Delving into the Latest Updates on NeuroVia, Inc. with Synapse

Phase I/II, Open-Label, Dose Escalation Study of the Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Childhood Cerebral Adrenoleukodystrophy (CCALD)

This is a phase I/II, open label dose escalation study of multiple dose levels of NV1205 with a long-term treatment phase.

开始日期2018-08-01

申办/合作机构

NeuroVia, Inc.

NCT03278899 / Unknown statusN/A

A Non-interventional Study to Prospectively Assess Baseline Status and Disease Progression in Male Children With X-Linked Adrenoleukodystrophy

This is a non-interventional, multi-center study that follows general principles of periodic assessment of X-ALD patients in routine practice. No study drug treatment will be given and no changes to patient treatment are necessary.

开始日期2018-02-16

申办/合作机构

NeuroVia, Inc.

100 项与 NeuroVia, Inc. 相关的临床结果

登录后查看更多信息

0 项与 NeuroVia, Inc. 相关的专利（医药）

登录后查看更多信息

100 项与 NeuroVia, Inc. 相关的药物交易

登录后查看更多信息

100 项与 NeuroVia, Inc. 相关的转化医学

登录后查看更多信息